Cucurbitacin E inhibits osteosarcoma cells proliferation and invasion through attenuation of PI3K/AKT/mTOR signalling

Ying Wang1, Shumei Xu2, Yaochi Wu3

  • 1Department of Acupuncture, Tuina and Traumatology, the Sixth People's Hospital Affiliated to Shanghai Jiaotong University, Shanghai 200233, China.

Bioscience Reports
|September 23, 2016
PubMed

Insights

Cucurbitacin E (CuE) effectively inhibits osteosarcoma (OS) growth and invasion by targeting the PI3K/Akt/mTOR pathway. This study highlights CuE as a potential anti-cancer agent for OS treatment.

Area of Science:

  • Pharmacology
  • Oncology
  • Molecular Biology

Background:

  • Cucurbitacin E (CuE), a plant-derived triterpenoid, shows anti-tumor properties.
  • The anti-cancer mechanisms of CuE in osteosarcoma (OS) remain largely unexplored.

Purpose of the Study:

  • To investigate the efficacy of CuE against OS cell proliferation and invasion.
  • To elucidate the molecular mechanisms underlying CuE's effects on OS.

Main Methods:

  • Cell Counting Kit-8 assay for proliferation.
  • Flow cytometry for apoptosis and cell cycle analysis.
  • Transwell assays for invasion and Western blotting for protein expression.

Main Results:

  • CuE significantly inhibited OS cell growth, invasion, and metastasis.
  • CuE induced cell cycle arrest and apoptosis.
  • CuE suppressed the PI3K/Akt/mTOR pathway and epithelial-mesenchymal transition (EMT).

Conclusions:

  • CuE demonstrates potent anti-tumor activity against osteosarcoma in vitro and in vivo.
  • Inhibition of the PI3K/Akt/mTOR pathway and EMT is a key mechanism for CuE's anti-cancer effects in OS.
  • CuE represents a promising therapeutic candidate for osteosarcoma.

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

5.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.6K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.1K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.8K